The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.
The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.